ALLMedicine™ Edema Center

Mar 25th, 2023 - Congenital lymphatic anomalies (LAs) arise due to defects in lymphatic development and often present in utero as pleural effusion, chylothorax, nuchal and soft tissue edema, ascites, or hydrops. Many LAs are caused by single nucleotide variants wh...

Mar 24th, 2023 - To investigate the predictive value of noncontrast computed tomography (NCCT) models based on radiomics features and machine learning (ML) for early perihematomal edema (PHE) expansion in patients with spontaneous intracerebral hemorrhage (ICH). W...

Mar 22nd, 2023 - To better understand the level of agreement among retina specialists on the role of inflammation in diabetic retinopathy (DR) and diabetic macular edema (DME), and the use of 0.19-mg fluocinolone acetonide (FAc) implant in DME treatment, a consens...

Mar 22nd, 2023 - Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes mellitus. DKA associated with shock is a rare condition that occurs due to the fluid deficit or septic shock. It is not easy to differentiate these two conditions by clinic...

Mar 21st, 2023 - To investigate morphological changes of intraretinal cyst in association with visual acuity following treatment for diabetic macular edema. This retrospective study enrolled 105 eyes from 105 treatment naïve patients with diabetic macular edema fo...

Dec 6th, 2011 - To describe the underlying principles used to develop a web-based algorithm that incorporated intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in a Diabetic Retinopathy Clinical Research N...

Aug 24th, 2022 - Vabysmo (fraicimab) Vabysmo (faricimab) – First bispecific antibody for treatment of adults with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). Faricimab targets 2 distinct pathways – angiopoietin-2 (Ang...

Jun 27th, 2022 - The efficacy, durability, and safety of faricimab (Vabysmo, Genentech/Roche) for diabetic macular edema (DME) seen at 1 year extends to 2 years, according to results of two pivotal trials. As previously reported, in January 2022, the US Food and D...

Jun 8th, 2022 - The US Food and Drug Administration (FDA) has approved brolucizumab (Beovu) for treatment of diabetic macular edema (DME), but included a warning about retinal vasculitis and retinal vascular occlusion. In clinical trials, patients needed fewer in...

Jan 28th, 2022 - The US Food and Drug Administration (FDA) today approved faricimab (Vabysmo, Genentech/Roche) to treat diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Compared with antivascular endothelial growth factor (VEGF...

Nov 30th, 2021 - Though primary efficacy results have yet to be published, new safety findings from two large, randomized trials of aducanumab offer details on which patients are more likely to experience complications associated with the controversial Alzheimer's...